Lexaria Bioscien Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lexaria Bioscien has an operating margin of -1683.0%, meaning the company retains $-1683 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -1239.2% the prior year.
Lexaria Bioscien's revenue surged 52.0% year-over-year to $706K, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Lexaria Bioscien carries a low D/E ratio of 0.53, meaning only $0.53 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.32, Lexaria Bioscien holds $2.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 73/100.
While Lexaria Bioscien generated -$10.5M in operating cash flow, capex of $25K consumed most of it, leaving -$10.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Lexaria Bioscien passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Lexaria Bioscien generates $0.88 in operating cash flow (-$10.5M OCF vs -$11.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Lexaria Bioscien (LEXXW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Lexaria Bioscien generated $706K in revenue in fiscal year 2025. This represents an increase of 52.0% from the prior year.
Lexaria Bioscien's EBITDA was -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 107.1% from the prior year.
Lexaria Bioscien generated -$10.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 109.4% from the prior year.
Lexaria Bioscien reported -$11.9M in net income in fiscal year 2025. This represents a decrease of 105.4% from the prior year.
Lexaria Bioscien earned $-0.66 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 40.4% from the prior year.
Lexaria Bioscien held $1.8M in cash against $0 in long-term debt as of fiscal year 2025.
Lexaria Bioscien had 20M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Lexaria Bioscien's gross margin was 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.
Lexaria Bioscien's operating margin was -1683.0% in fiscal year 2025, reflecting core business profitability. This is down 443.9 percentage points from the prior year.
Lexaria Bioscien's net profit margin was -1686.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 437.7 percentage points from the prior year.
Lexaria Bioscien invested $8.2M in research and development in fiscal year 2025. This represents an increase of 249.0% from the prior year.
Lexaria Bioscien invested $25K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 42.7% from the prior year.
LEXXW Income Statement
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $174K0.0% | $174K-5.4% | $184K+119.0% | $84K-42.1% | $145K-4.1% | $151K+94.7% | $78K |
| Cost of Revenue | $0 | $0 | $0-100.0% | $3K | $0 | $0-100.0% | $5K-62.2% | $13K |
| Gross Profit | $0-100.0% | $174K0.0% | $174K-4.0% | $181K+115.7% | $84K-42.1% | $145K-1.0% | $146K+125.5% | $65K |
| R&D Expenses | $671K-75.3% | $2.7M+61.2% | $1.7M-13.7% | $2.0M+240.8% | $573K+133.2% | $246K-57.2% | $574K-65.0% | $1.6M |
| SG&A Expenses | $902K-25.2% | $1.2M-2.6% | $1.2M+34.9% | $919K-26.7% | $1.3M+121.0% | $567K-20.2% | $711K-13.8% | $825K |
| Operating Income | -$1.6M+58.0% | -$3.8M-36.3% | -$2.8M-2.2% | -$2.7M-54.4% | -$1.7M-160.9% | -$668K+41.4% | -$1.1M+52.6% | -$2.4M |
| Interest Expense | N/A | N/A | N/A | N/A | $0+100.0% | -$1 | N/A | $15K |
| Income Tax | $2K | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Net Income | -$1.6M+57.9% | -$3.8M-39.7% | -$2.7M-0.4% | -$2.7M-51.7% | -$1.8M-174.3% | -$650K+44.9% | -$1.2M+50.3% | -$2.4M |
| EPS (Diluted) | $-0.07+66.7% | $-0.21-40.0% | $-0.15+6.3% | $-0.16-23.1% | $-0.13-116.7% | $-0.06+53.8% | $-0.13 | N/A |
LEXXW Balance Sheet
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.1M-10.2% | $6.7M-22.3% | $8.7M-11.4% | $9.8M+10.4% | $8.9M+39.6% | $6.4M+75.1% | $3.6M+17.6% | $3.1M |
| Current Assets | $5.4M-7.6% | $5.8M-24.8% | $7.7M-12.5% | $8.8M+11.7% | $7.9M+45.8% | $5.4M+101.1% | $2.7M+25.2% | $2.2M |
| Cash & Equivalents | $4.3M-6.5% | $4.6M-29.2% | $6.5M-19.5% | $8.1M+24.3% | $6.5M+38.1% | $4.7M+140.8% | $2.0M+44.5% | $1.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Accounts Receivable | $88K-75.4% | $358K+8.1% | $331K+25.7% | $263K+70.6% | $154K-56.7% | $357K-33.2% | $535K+322.1% | $127K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.5M-3.0% | $1.6M-17.8% | $1.9M+379.5% | $400K-66.9% | $1.2M+491.9% | $204K-19.6% | $254K-37.1% | $404K |
| Current Liabilities | $1.5M-2.1% | $1.5M-18.3% | $1.8M+512.0% | $298K-72.9% | $1.1M+1245.4% | $82K-34.4% | $125K-53.5% | $268K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.9M-11.5% | $5.6M-22.3% | $7.1M-26.9% | $9.8M+21.6% | $8.0M+23.2% | $6.5M+74.2% | $3.7M+22.9% | $3.0M |
| Retained Earnings | -$65.1M-7.1% | -$60.8M-6.7% | -$57.0M-5.0% | -$54.3M-5.2% | -$51.6M-8.3% | -$47.6M-1.4% | -$46.9M-2.6% | -$45.8M |
LEXXW Cash Flow Statement
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$984K+72.5% | -$3.6M-139.3% | -$1.5M+45.1% | -$2.7M-44.1% | -$1.9M-205.3% | -$620K+47.6% | -$1.2M+27.1% | -$1.6M |
| Capital Expenditures | $0+100.0% | -$1-200.0% | $1-100.0% | $25K-42.7% | $43K | $0 | $0 | $0 |
| Free Cash Flow | -$984K+72.5% | -$3.6M-139.3% | -$1.5M+45.5% | -$2.8M-42.2% | -$1.9M-212.2% | -$620K+47.6% | -$1.2M+27.1% | -$1.6M |
| Investing Cash Flow | -$5K+73.8% | -$19K+30.3% | -$28K+26.2% | -$38K+45.7% | -$70K-22.1% | -$57K-42.4% | -$40K+41.5% | -$68K |
| Financing Cash Flow | $3.5M+105.7% | $1.7M+14311.7% | $12K-99.7% | $4.3M | $0-100.0% | $3.5M+89.8% | $1.8M+1595.1% | -$122K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LEXXW Financial Ratios
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 100.0%0.0pp | 100.0%+1.5pp | 98.5%-1.5pp | 100.0%0.0pp | 100.0%+3.2pp | 96.8%+13.2pp | 83.6% |
| Operating Margin | N/A | -2155.4%-574.4pp | -1581.0%-118.1pp | -1463.0%+611.9pp | -2074.9%-1614.2pp | -460.7%+292.3pp | -753.0%+2336.6pp | -3089.6% |
| Net Margin | N/A | -2177.6%-618.3pp | -1559.3%-89.3pp | -1470.0%+651.0pp | -2121.1%-1673.1pp | -448.0%+331.6pp | -779.6%+2272.3pp | -3051.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -26.4%+29.9pp | -56.2%-24.9pp | -31.3%-3.7pp | -27.6%-9.8pp | -17.8%-7.6pp | -10.2%+22.3pp | -32.5%+12.7pp | -45.3% |
| Current Ratio | 3.68-0.2 | 3.90-0.3 | 4.24-25.4 | 29.64+22.5 | 7.18-59.1 | 66.29+44.7 | 21.63+13.6 | 8.03 |
| Debt-to-Equity | 0.31+0.0 | 0.28+0.0 | 0.27+0.2 | 0.04-0.1 | 0.15+0.1 | 0.03-0.0 | 0.07-0.1 | 0.13 |
| FCF Margin | N/A | -2059.7%-1198.9pp | -860.9%+634.7pp | -1495.6%+11.7pp | -1507.2%-1079.9pp | -427.3%+353.8pp | -781.1%+1517.2pp | -2298.3% |
Similar Companies
Frequently Asked Questions
What is Lexaria Bioscien's annual revenue?
Lexaria Bioscien (LEXXW) reported $706K in total revenue for fiscal year 2025. This represents a 52.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lexaria Bioscien's revenue growing?
Lexaria Bioscien (LEXXW) revenue grew by 52% year-over-year, from $464K to $706K in fiscal year 2025.
Is Lexaria Bioscien profitable?
No, Lexaria Bioscien (LEXXW) reported a net income of -$11.9M in fiscal year 2025, with a net profit margin of -1686.0%.
What is Lexaria Bioscien's earnings per share (EPS)?
Lexaria Bioscien (LEXXW) reported diluted earnings per share of $-0.66 for fiscal year 2025. This represents a -40.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lexaria Bioscien's EBITDA?
Lexaria Bioscien (LEXXW) had EBITDA of -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lexaria Bioscien's gross margin?
Lexaria Bioscien (LEXXW) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Lexaria Bioscien's operating margin?
Lexaria Bioscien (LEXXW) had an operating margin of -1683.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Lexaria Bioscien's net profit margin?
Lexaria Bioscien (LEXXW) had a net profit margin of -1686.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Lexaria Bioscien's free cash flow?
Lexaria Bioscien (LEXXW) generated -$10.5M in free cash flow during fiscal year 2025. This represents a -109.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lexaria Bioscien's operating cash flow?
Lexaria Bioscien (LEXXW) generated -$10.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Lexaria Bioscien's total assets?
Lexaria Bioscien (LEXXW) had $4.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lexaria Bioscien's capital expenditures?
Lexaria Bioscien (LEXXW) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Lexaria Bioscien spend on research and development?
Lexaria Bioscien (LEXXW) invested $8.2M in research and development during fiscal year 2025.
How many shares does Lexaria Bioscien have outstanding?
Lexaria Bioscien (LEXXW) had 20M shares outstanding as of fiscal year 2025.
What is Lexaria Bioscien's current ratio?
Lexaria Bioscien (LEXXW) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.
What is Lexaria Bioscien's debt-to-equity ratio?
Lexaria Bioscien (LEXXW) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lexaria Bioscien's return on assets (ROA)?
Lexaria Bioscien (LEXXW) had a return on assets of -285.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lexaria Bioscien's cash runway?
Based on fiscal year 2025 data, Lexaria Bioscien (LEXXW) had $1.8M in cash against an annual operating cash burn of $10.5M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lexaria Bioscien's Piotroski F-Score?
Lexaria Bioscien (LEXXW) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lexaria Bioscien's earnings high quality?
Lexaria Bioscien (LEXXW) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Lexaria Bioscien?
Lexaria Bioscien (LEXXW) scores 53 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.